KLDO - Kaleido BioSciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.05
+0.05 (+0.83%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.00
Open5.88
Bid5.00 x 1000
Ask8.23 x 1000
Day's Range5.52 - 6.14
52 Week Range2.82 - 19.00
Volume53,046
Avg. Volume168,220
Market Cap184.044M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.36
Earnings DateMay 29, 2020 - Jun 08, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.38
  • Kaleido Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
    GlobeNewswire

    Kaleido Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

    - Results from three clinical studies in 2019 support Phase 2 development program in urea cycle disorders (UCD) and advancement of hepatic encephalopathy program into next.

  • Kaleido Biosciences Announces Collaboration with Janssen to Explore the Potential for Microbiome Metabolic Therapies (MMT™) to Prevent Childhood-Onset of Atopic, Immune and Metabolic Conditions by Promoting Healthy Function of the Gut Microbiome
    GlobeNewswire

    Kaleido Biosciences Announces Collaboration with Janssen to Explore the Potential for Microbiome Metabolic Therapies (MMT™) to Prevent Childhood-Onset of Atopic, Immune and Metabolic Conditions by Promoting Healthy Function of the Gut Microbiome

    The collaboration will explore the potential for Kaleido’s Microbiome Metabolic Therapies (MMT™) to prevent the onset of childhood allergy and other atopic, immune and metabolic conditions by driving specific microbiome features which support an appropriate maturation of the infant immune system. A primary focus of the research will be to utilize Kaleido’s proprietary ex vivo screening platform to identify MMTs candidates that support the growth of specific beneficial microbes.

  • Kaleido Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
    GlobeNewswire

    Kaleido Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference

    LEXINGTON, Mass., Jan. 06, 2020 -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome.

  • Here is What Hedge Funds Think About Kaleido BioSciences, Inc. (KLDO)
    Insider Monkey

    Here is What Hedge Funds Think About Kaleido BioSciences, Inc. (KLDO)

    The market has been volatile in the last few months as the Federal Reserve finalized its rate cuts and uncertainty looms over trade negotiations with China. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by more than 10 percentage […]

  • Flagship Unveils Newest Pioneering Platform: Ring Therapeutics
    PR Newswire

    Flagship Unveils Newest Pioneering Platform: Ring Therapeutics

    Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a new viral vector platform based on its groundbreaking work on the human commensal virome. Ring's technology promises to address many of the limitations of current DNA and gene therapies, such as limited access to diverse tissues, inability to redose, risk of genomic integration, and poor tolerability. Ring's founding and continued development are resourced by an initial capital commitment of $50 million from Flagship Pioneering.

  • Kaleido Biosciences to Advance KB174 for Hepatic Encephalopathy Based on Positive Top-Line Results from a Clinical Study in Patients with Cirrhosis
    GlobeNewswire

    Kaleido Biosciences to Advance KB174 for Hepatic Encephalopathy Based on Positive Top-Line Results from a Clinical Study in Patients with Cirrhosis

    - KB174 Exceeded the Targeted Reduction in a Biomarker of Microbiome Ammonia Production- KB174 Was Well Tolerated and No Clinically Significant or Serious Treatment-Related.

  • Kaleido Biosciences Appoints William Duke as Chief Financial Officer
    GlobeNewswire

    Kaleido Biosciences Appoints William Duke as Chief Financial Officer

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced the appointment of William Duke as Chief Financial Officer (CFO), effective November 25, 2019. Mr. Duke brings nearly 20 years of experience in CFO and senior finance roles, including more than a decade within the life sciences industry. “Bill has demonstrated a track record of leadership and corporate finance acumen throughout his career and is experienced in the life sciences industry and capital markets,” said Alison Lawton, President and Chief Executive Officer of Kaleido.

  • Kaleido BioSciences, Inc. (KLDO) Is Burning These Hedge Funds
    Insider Monkey

    Kaleido BioSciences, Inc. (KLDO) Is Burning These Hedge Funds

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing more than 730 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of June […]

  • Kaleido Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update
    GlobeNewswire

    Kaleido Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    - Executing Pipeline Towards Key Clinical Data Readouts in Q4 2019 and 2020 - Focusing Resources on Pipeline Programs and Extending Cash Runway   LEXINGTON, Mass., Oct. 30,.

  • World Wide Fund for Nature uses Ethereum-based Kaleido to conjure up Impactio
    Decrypt

    World Wide Fund for Nature uses Ethereum-based Kaleido to conjure up Impactio

    WWF thinks the Ethereum blockchain may hold the key to better fundraising—but not in the way you're thinking.

  • Kaleido Biosciences and Washington University School of Medicine to Collaborate on Exploring the Influence of Microbiome Metabolic Therapies (MMT™) on Physiology and Metabolism
    GlobeNewswire

    Kaleido Biosciences and Washington University School of Medicine to Collaborate on Exploring the Influence of Microbiome Metabolic Therapies (MMT™) on Physiology and Metabolism

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, has entered into a research collaboration with Jeffrey Gordon, M.D., Director of the Edison Family Center for Genome Sciences and Systems Biology at Washington University School of Medicine, to explore the influence of Microbiome Metabolic Therapies (MMT™) on microbial and host physiology and metabolism. Dr. Gordon is considered the founder of the modern microbiome field and is recognized worldwide for his fundamental work in uncovering the underpinnings of the relationships between microorganisms residing in the gut and mammalian physiology. Under the collaboration, gnotobiotic preclinical models will be combined with innovative experimental and computational methods to further identify molecular pathways by which Kaleido’s MMTs can modify the functional configuration of the gut microbiome and its metabolic outputs.

  • Kaleido Biosciences Presents Ex Vivo Data of KB109 Demonstrating Reduction of Multi-drug Resistant Pathogens at IDWeek 2019™
    GlobeNewswire

    Kaleido Biosciences Presents Ex Vivo Data of KB109 Demonstrating Reduction of Multi-drug Resistant Pathogens at IDWeek 2019™

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced that ex vivo and in vivo data evaluating its Microbiome Metabolic Therapies (MMT™) are being presented at IDWeek 2019™ and the Keystone Symposia on the Microbiome: Therapeutic Implications. Kaleido is advancing MMT candidate, KB109, in clinical development to decrease colonization with multi-drug resistant (MDR) pathogens by selectively enhancing the growth of beneficial bacteria in the gut and reducing the risk of infection.

  • Kaleido Biosciences Announces Appointment of Jean Mixer to its Board of Directors
    GlobeNewswire

    Kaleido Biosciences Announces Appointment of Jean Mixer to its Board of Directors

    Ms. Mixer has more than 25 years of experience in healthcare and is currently Chief Digital Transformation Officer and Vice President, Strategy at Boston Children’s Hospital.  Previously, she launched and ran her own consulting firm, and served for more than a decade as a partner at the Boston Consulting Group.  Ms. Mixer has experience across the healthcare industry, including working with executive management and Boards of leading academic medical centers, integrated healthcare delivery networks, payers, pharmacy/PBMs and biopharmaceutical and medical device companies.

  • Benzinga

    The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 26.) AstraZeneca plc (NYSE: AZN ) GlaxoSmithKline ...

  • Kaleido Biosciences Announces CFO Transition
    GlobeNewswire

    Kaleido Biosciences Announces CFO Transition

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced that Joshua Brumm will step down as Chief Operating and Chief Financial Officer effective October 11, 2019, to serve as President and Chief Executive Officer of a biotechnology company. Kaleido will initiate a search for a Chief Financial Officer and Richard Scalzo, Corporate Controller, has been appointed to serve as Principal Accounting Officer and, in the interim, will assume certain of Mr. Brumm’s responsibilities. Mr. Brumm will continue as an advisor to Kaleido through December 31, 2019.

  • Kaleido Biosciences to Collaborate with Gustave Roussy Cancer Center to Develop Microbiome Metabolic Therapies (MMT™) in Immuno-oncology
    GlobeNewswire

    Kaleido Biosciences to Collaborate with Gustave Roussy Cancer Center to Develop Microbiome Metabolic Therapies (MMT™) in Immuno-oncology

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced plans to develop Microbiome Metabolic Therapies (MMT™) to enhance the effects of cancer immunotherapies under a new research collaboration with Gustave Roussy, the largest cancer treatment center in Europe. Gustave Roussy is a pioneer in cancer immunotherapy and research into the relationship between the microbiome and cancer. Kaleido’s MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes.

  • Kaleido Biosciences Presents Data from Clinical Study of KB195 in Patients with Urea Cycle Disorders at Society for the Study of Inborn Errors of Metabolism Annual Symposium
    GlobeNewswire

    Kaleido Biosciences Presents Data from Clinical Study of KB195 in Patients with Urea Cycle Disorders at Society for the Study of Inborn Errors of Metabolism Annual Symposium

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced data from a clinical study of KB195 in patients with urea cycle disorders (UCD) are being featured in a poster presentation during the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium in Rotterdam, the Netherlands, September 3-6, 2019. The gut microbiome plays a significant role in the production and consumption of ammonia, which is central to the pathogenesis of several diseases, including UCD.  UCD are a group of serious, life-threatening, rare genetic diseases, which can lead to hyperammonemia, a metabolic condition generally categorized by elevated levels of ammonia in the blood.  KB195, a novel Microbiome Metabolic Therapy (MMT™), designed to reduce net ammonia production by modulating the metabolic output and profile of the microbiome, is in development as a potential treatment for UCD.

  • Kaleido Biosciences to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
    GlobeNewswire

    Kaleido Biosciences to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

    LEXINGTON, Mass., Aug. 29, 2019 -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome.

  • Kaleido Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update
    GlobeNewswire

    Kaleido Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    LEXINGTON, Mass., Aug. 01, 2019 -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of.

  • Kaleido Biosciences to Present at the 39th Annual Canaccord Genuity Growth Conference
    GlobeNewswire

    Kaleido Biosciences to Present at the 39th Annual Canaccord Genuity Growth Conference

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced that management will participate in a fireside chat at the 39th Annual Canaccord Genuity Growth Conference in Boston, MA on Thursday, August 8, 2019 at 1:00 p.m. ET. A live audio webcast will be available through the Investors & Media section of Kaleido’s website at https://investors.kaleido.com/events-presentations.  An archived replay will be accessible for 90 days following the event. Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health.

  • Kaleido Biosciences Appoints Jerald Korn as General Counsel and Corporate Secretary
    GlobeNewswire

    Kaleido Biosciences Appoints Jerald Korn as General Counsel and Corporate Secretary

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced the appointment of Jerald Korn as General Counsel and Corporate Secretary, reporting to President and Chief Executive Officer, Alison Lawton. “Jerald brings an in-depth understanding of strategy and operations in growth-stage organizations and more than 15 years of experience guiding the executive teams of some of the leading public life science companies,” said Alison Lawton, President and Chief Executive Officer of Kaleido. “As we continue to advance our business, Kaleido will benefit from Jerald’s proven success helping companies navigate expansion, transactions and commercializing products that can improve patients’ lives.

  • How Many Kaleido BioSciences, Inc. (NASDAQ:KLDO) Shares Did Insiders Buy, In The Last Year?
    Simply Wall St.

    How Many Kaleido BioSciences, Inc. (NASDAQ:KLDO) Shares Did Insiders Buy, In The Last Year?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...

  • Kaleido Biosciences Announces Appointment of Theo Melas-Kyriazi to its Board of Directors
    GlobeNewswire

    Kaleido Biosciences Announces Appointment of Theo Melas-Kyriazi to its Board of Directors

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced that Theo Melas-Kyriazi, Executive Partner at Flagship Pioneering, has been appointed to its Board of Directors. In addition, the Company announced that Noubar Afeyan, Ph.D., co-founder of Kaleido and CEO of Flagship Pioneering, is stepping down after serving as a Board member since Kaleido’s founding within Flagship Labs in 2015.

  • Kaleido Biosciences to Highlight Chemistry-Driven Approach at Microbiome Movement – Drug Development Summit
    GlobeNewswire

    Kaleido Biosciences to Highlight Chemistry-Driven Approach at Microbiome Movement – Drug Development Summit

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced that members of the Company’s leadership team will be featured speakers at the 4th Microbiome Movement – Drug Development Summit which is being held today through June 28, 2019 in Boston.

  • Kaleido Biosciences to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
    GlobeNewswire

    Kaleido Biosciences to Present at the Goldman Sachs 40th Annual Global Healthcare Conference

    LEXINGTON, Mass., June 03, 2019 -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging.